Regeneron Pharmaceuticals, Inc. Overview
Pro stress-test →Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Full year 2025 revenues increased 1% to $14.3 billion. The company demonstrated strong 2025 commercial performance, particularly within its retina and immunology franchises.
Strategic Profile
Pro stress-test →Regeneron operates as a unique biopharmaceutical company built on proprietary platforms such as VelocImmune technology and the Regeneron Genetics Center, enabling rapid discovery of therapeutic candidates and efficient delivery of innovative medicines. The company's platform-driven approach delivered 14 internally discovered approvals over the past 15 years, averaging roughly one major approval annually. 2026 is framed as a pivotal year, with multiple regulatory filings, clinical milestones, and new product launches on the horizon.
Competitive Landscape
Pro stress-test →Regeneron competes in the immuno-oncology and ophthalmology markets against major pharma and biotech companies. In immunology, competitors include Sanofi (Dupixent partner), AstraZeneca, and Novartis in the allergy/asthma space. In ophthalmology, the company faces competitive pressure from other anti-VEGF therapies with its EYLEA HD platform. The company's oncology programs like Libtayo position it against checkpoint inhibitor developers.
Industry Context
Regeneron Pharmaceuticals, Inc. operates in Biopharmaceuticals & Therapeutics - Specialty Pharma/Biotech.
Key facts
Founded: 1989 · Headquarters: Tarrytown, US · Employees: N/A · Revenue: $14.3B · Market cap: N/A